Intelligence · Patents
Patents expiring in 2029
Annual patent cliff calendar for 2029 — US pharmaceutical patents by expiration date.
- Patents
- 713
Quick answer
713 indexed pharmaceutical patents have expiration dates in 2029. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 7608268
Ferritin fusion proteins for use in vaccines and other applications
granted -
US 7608632
Sulfonamide inhibitors of aspartyl protease
granted -
US 7608693
High affinity human antibodies to human IL-4 receptor
granted -
US 7612091
Caspase inhibitors and uses thereof
granted -
US 7612044
Melanoma antigens and their use in diagnostic and therapeutic methods
granted -
US 7611693
Mechanism-based targeted pancreatic beta cell imaging and therapy
granted -
US 7611532
Coated implantable medical device
granted -
US 7611533
Coated implantable medical device
granted -
US 7611728
Osmotic delivery of therapeutic compounds by solubility enhancement
granted -
US 7611885
Pharmaceutically compatible method for purifying intact bacterial minicells
granted -
US 7612064
Sulfopyrroles
granted -
US 7612203
Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof
granted -
US 7612107
Treatment and inhibition of disease conditions using flexible heteroarotinoids
granted -
US 7612188
Modified vitamin K. dependent polypeptides
granted -
US 7612065
Inhibitors of c-JUN N-terminal kinases (JNK)
granted -
US 7612073
Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring
granted -
US 7611722
Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material, and process and tooling for producing it
granted -
US 7612037
Cross-linked glycopeptide-cephalosporin antibiotics
granted -
US 7611704
Compositions and methods for treating viral infections using antibodies and immunoconjugates to aminophospholipids
granted -
US 7612093
Compositions of treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds in combination therapy
granted -
US 7615208
Metal ion-labeled bis-aminoethanethiol-targeting ligand conjugates, compositions, and methods for tissue-specific disease imaging
granted -
US 7615223
Selected immunoconjugates for binding to aminophospholipids
granted -
US 7615230
Method for decreasing sebum production
granted -
US 7615582
One-pack type adhesive composition for dental use
granted -
US 7615566
Substituted pyrrolidine and related compounds
granted -
US 7615227
Use of CpG oligodeoxynucleotides to induce angiogenesis
granted -
US 7615220
High affinity human antibodies to human IL-18 receptor
granted -
US 7615618
Oligonucleotides comprising a non-phosphate backbone linkage
granted -
US 7615573
Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors
granted -
CA 2723411
PROCEDE
granted -
US 7618986
Method of treating latent tuberculosis
granted -
US 7619005
Methods for treating cognitive impairment in humans with Multiple Sclerosis
granted -
US 7618936
Methods for treating and diagnosing cancer with WNT inhibitory Factor-1 (WIF-1)
granted -
US 7618632
Method of treating or ameliorating an immune cell associated pathology using GITR ligand antibodies
granted -
US 7618630
Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
granted -
US 7618623
Hybrid adeno-retroviral vector for the transfection of cells
granted -
US 7618616
Skin-protective compositions effective against vesicants and percutaneous chemical agents
granted -
US 7618627
Method of increasing radiation sensitivity by inhibition of beta one integrin
granted -
US 7618976
Methods for the production of sildenafil base and citrate salt
granted -
US 7619117
Rasagiline formulations and processes for their preparation
granted -
US 7619112
Optical resolution of 3-carbamoylmethyl-5-methyl hexanoic acid
granted -
US 7619057
MHC class II restricted T cell epitopes from the cancer antigen, NY ESO-1
granted -
US 7619000
S-dimethylarsino-thiosuccinic acid S-dimethylarsino-2-thiobenzoic acid S-(dimethylarsino) glutathione as treatments for cancer
granted -
EP 2117603
TARGETING UND THERAPEUTISCHE VERBINDUNGEN UND GASGEFÜLLTE MIKROVESIKEL MIT DIESEN VERBINDUNGEN
granted -
US 7622467
Aryl aniline derivatives as β2 adrenergic receptor agonists
granted -
US 7622123
Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines
granted -
US 7622113
Monoclonal antibodies that bind or neutralize dengue virus
granted -
US 7622107
Recombinant intracellular pathogen immunogenic compositions and methods for use
granted
Frequently asked questions
How many pharma patents expire in 2029?
713 published patents in our USPTO index have expiration dates falling in calendar year 2029.